Skip to main content
. Author manuscript; available in PMC: 2010 May 1.
Published in final edited form as: Glia. 2009 May;57(7):777–790. doi: 10.1002/glia.20805

Figure 5. Tamoxifen treatment inhibits relapsing-remitting EAE in female SJL mice.

Figure 5

(A, B) Eight SJL mice were implanted with time-release pellets containing 25 mg of tamoxifen and 8 mice were treated with placebo pellets one week prior to immunization with PLP 139-151 and CFA. The mice were monitored daily and scored for EAE disability. The mean daily EAE score for each group is presented in panel A. The cumulative disease index (CDI) for each group show in panel B. (C) The CDI from B10.PL mice implanted with time-release tamoxifen or 17β-estradiol (E2) pellets (at 0.1 mg or 2.5 mg) or placebo and immunized with MBP Ac1-11 and CFA. (D) Spinal cord sections from the mice in the experiment described in panel C were immunolabeled with an anti-MBP antibody. Note the reduction in myelin staining in the white matter (arrows) of placebo-treated mice compared to mice treated with either 17β-estradiol or tamoxifen. *Statistically significant difference in the cumulative disease index (CDI) between tamoxifen treated and placebo, p <= 0.005.